EMA Workload Takes a Brexit Hit
Brexit preparedness: EMA to further temporarily scale back and suspend activities
The European Medicines Agency (EMA) will launch the next phase (phase 3) of its business continuity plan on 1 October 2018 at the latest, allowing the Agency to safeguard core activities related to the evaluation and supervision of medicines, while intensifies its preparations for the move to Amsterdam in March 2019 and cope with significant staff loss.
Temporary cuts in activities are required because the Agency will lose more staff than initially anticipated. Staff who will not relocate to Amsterdam have already started to leave the Agency and this trend is expected to accelerate. In addition, due to the employment rules in the Netherlands, 135 short-term contract staff will no longer be able to work for EMA. Overall, EMA expects a staff loss of about 30%, with a high degree of uncertainty regarding mid-term staff retention.
Activities initially impacted by phase 3 include:
- Collaboration at international level
- Development and revision of guidelines
- Holding of non-product-related working parties
- Programmes and projects, where activities in relation to project governance will be reduced in line with the reduction/suspension of projects;
- Organisation and attendance at stakeholder meetings;
- Clinical data publication